While the cure rates for pediatric acute lymphoblastic leukemia (ALL) have improved over the past few decades. Infants with ALL have not benefited from advances in therapies and continue to have a dismal prognosis. In this proposal, we address this unmet need by investigating a novel model to understand the cellular and molecular changes that occur during infant ALL onset and progression and compare these changes to healthy blood cell development.